Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
TVRD Stock Chart & Stats
$3.16
--
Market closed
$3.16
--
Day’s Range― - ―
52-Week Range$2.75 - $43.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.55K
Market Cap
$28.52M
Enterprise Value$9.11M
Total Cash (Recent Filing)$30.81M
Total Debt (Recent Filing)$201.00K
Price to Earnings (P/E)―
Beta0.18
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding9,381,344
10 Day Avg. Volume1,070,842
30 Day Avg. Volume401,545
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue3.55
Enterprise Value/Gross Profit3.61
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$8.33Price Target Upside163.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Drug FormulationThe TTI-109 prodrug is designed to convert to the active agent after entering the bloodstream and remain inert in the gut, which could improve gastrointestinal tolerability and expand the therapeutic window.
Financial RunwayReported cash resources are indicated to be sufficient to fund operations through multiple clinical milestones, reducing near‑term financing risk for the development programs.
Idiopathic Pulmonary Fibrosis EfficacyPost‑hoc analyses from the Phase 2 IPF study reported consistent favorable trends across imaging, biomarkers, and lung function for TTI‑101 versus placebo, suggesting STAT3 inhibition may reduce fibrosis and inflammation.
Bears Say
Research ObjectivityThe covering firm discloses commercial relationships with companies it covers, which may create conflicts of interest and could affect the perceived objectivity of analyst reports.
Safety And TolerabilityAdverse‑event‑driven discontinuations were higher when TTI‑101 was combined with another antifibrotic and gastrointestinal issues were concentrated in treated patients, leaving tolerability concerns that could affect development plans.
Trial InterpretabilityTopline efficacy results from the Phase 2 REVERT IPF trial were difficult to interpret because a large number of patients discontinued treatment and placebo performance exceeded expectations, complicating assessment of therapeutic benefit.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was $2.75 and its highest was $43.65 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is $28.52M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s upcoming earnings report date is May 19, 2026 which is in 33 days.
How were Tvardi Therapeutics’s earnings last quarter?
Tvardi Therapeutics released its earnings results on Mar 31, 2026. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.744 by -$0.036.
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 9,381,344 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Tvardi Therapeutics reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.744. Following the earnings report the stock price went down -5.66%.
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in TVRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tvardi Therapeutics
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
TVRD Stock 12 Month Forecast
Average Price Target
$8.33
▲(163.61% Upside)
Technical Analysis
Plus Therapeutics
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―
Ownership Overview
12.88% Insiders
7.86% Mutual Funds
12.51% Other Institutional Investors
60.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---